With a market capitalization (market cap) of $6.82B — a measure of how much the company is worth — Abivax S.A. ranks #1,146 among the 2,510 companies tracked, and 134th in Healthcare as of October 3, 2026. Shares trade at $92.88, down 2.33% on the day.
of 2,510 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series — they can diverge when the share count changes. Those returns are not a CAGR until you pick a start value, an ending value, and years. CAGR calculator. Market cap vs. stock price.
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation October 2, 2026. Ranking headline cap is the snapshot figure as of October 3, 2026.
| Year | As of | Market cap | Annual change | Year-end close |
|---|---|---|---|---|
| 2026 | Oct 2, 2026 | $7.4B | -21.10% | $92.88 |
| 2025 | Dec 31, 2025 | $9.38B | +1,927.48% | $134.85 |
| 2024 | Dec 31, 2024 | $462.43M | -10.50% | $7.32 |
| 2023 | Dec 29, 2023 | $516.71M | — | $10.70 |
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
Ranking figure $6.82B as of October 3, 2026.
Abivax S.A.'s ranking market cap is the provider-reported capitalization on the same snapshot as the rest of this site, with a share price of $92.88 as of October 2, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $7.4B on October 2, 2026. See how the ranking works.
The ranking snapshot ($6.82B as of October 3, 2026) is FMP company-screener market cap. The historical observation ($7.4B on October 2, 2026) is FMP historical-market-capitalization for the same ticker. The live quote market cap agrees with the ranking snapshot. This listing is an ADR. This site does not have an ADS ratio, so it does not rescale either figure. This page does not replace one series with the other.
Live shares outstanding are not on the quote used for price, so this page does not invent a current share count. Shares outstanding vs. float.
The latest annual report (FY 2025) used a weighted-average 69,527,315 shares. That figure is an average for the year, not the live count in the market-cap formula.
Multiplying the latest price by those FY 2025 weighted-average shares would give about $6.46B. The ranking uses the provider's reported market cap instead, which reflects a current share count rather than that annual average.
This listing is an ADR. The market cap here is for the U.S. listing we rank; we do not have an ADR ratio, so we do not scale this figure to the parent company's local share count.
Book equity: assets minus liabilities on the latest annual report.
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Undefined when revenue is zero
Undefined when revenue is zero
Undefined when revenue is zero
FY 2025
FY 2025
Undefined when revenue is zero
FY 2025
Undefined when revenue is zero
FY 2025
FY 2025
FY 2025
FY 2025
Not in this snapshot
FY 2025 net worth
Largest U.S.-listed names in the same FMP sector — not a hand-picked competitor set.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #14 | Eli Lilly and Company LLY | $1.08T | -0.61% |
| #21 | Johnson & Johnson JNJ | $617.01B | -1.02% |
| #24 |
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV.
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2025.
Visit websiteAs of October 3, 2026, Abivax S.A. (ABVX) is worth $6.82B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2025, Abivax S.A.’s book equity is about $455.01M. Market cap is the market value of the outstanding shares. As of October 3, 2026, its market cap is $6.82B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
Abivax S.A. ranks #1,146 among the 2,510 companies tracked on MarketCapLens. In Healthcare it ranks #134 of 350.
Fundamentals are annual. Figures labeled with their fiscal year. Live ratios use the current price against those annual earnings.
Too little price history
Over the past year, market cap and share price moved by different amounts. Share count can change independently of price. What changes market cap.
Not in this snapshot
FY 2025
| $464.35B |
| +1.11% |
| #36 | Merck & Co., Inc. MRK | $356.4B | +0.34% |
| #38 | UnitedHealth Group Incorporated UNH | $337.74B | +1.83% |
| #52 | Novartis AG NVS | $268B | -0.04% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #1143 | The Macerich Company MAC | $6.86B | +2.26% |
| #1144 | Celsius Holdings, Inc. CELH | $6.84B | -2.41% |
| #1145 | AAON, Inc. AAON | $6.82B | +1.20% |
| #1147 | Qualys, Inc. QLYS | $6.8B | +2.97% |
| #1148 | Kanzhun Limited BZ | $6.79B | -0.80% |
| #1149 | PACS Group, Inc. PACS | $6.78B | +4.44% |
Abivax S.A.’s ranking market cap of $6.82B comes from the same snapshot as the rest of this site, as of October 3, 2026. It is not share price multiplied by the FY 2025 weighted-average share count of 69,527,315. The ranking snapshot ($6.82B as of October 3, 2026) is FMP company-screener market cap. The historical observation ($7.4B on October 2, 2026) is FMP historical-market-capitalization for the same ticker. The live quote market cap agrees with the ranking snapshot. This listing is an ADR. This site does not have an ADS ratio, so it does not rescale either figure. This page does not replace one series with the other.
Over the past year, Abivax S.A.’s market cap is up 28.39%, using historical market-cap records rather than today’s share count applied to past prices.
Abivax S.A. (ABVX) shares trade at $92.88, down 2.33% on the day, as of October 3, 2026.
Live P/E is share price divided by annual earnings per share. Sales-based ratios such as price/sales and operating margin are also blank when revenue is zero — not a 0× multiple.